The Food and Drug Administration today proposed reclassifying surgical staplers for internal use as moderate-risk rather than low-risk medical devices. The change would allow the agency to require premarket review of the devices and establish special controls such as mandatory performance testing of the device’s features, usability and labeling. In addition, FDA announced draft guidance to help manufacturers ensure their labeling provides adequate information for use, and a May 30 advisory committee meeting to receive expert input on the proposed reclassification and guidance. The agency has received reports of more than 9,000 serious injuries and 366 patient deaths associated with the devices since 2011, and last month issued additional safety recommendations for health care providers using the devices.

Related News Articles

Headline
Medtronic has recalled certain MiniMed insulin pumps due to cybersecurity risks, and will provide alternative pumps to the estimated 4,000 U.S. patients using…
Headline
The Joint Commission yesterday recommended that health care organizations review cleaning and disinfection instructions for tonometers and other ophthalmology…
Headline
The Food and Drug Administration last week alerted health care providers and patients that batteries in certain Medtronic implantable pacemakers and cardiac…
Headline
The Centers for Medicare…
Headline
The Food and Drug Administration today ordered manufacturers to immediately stop selling and distributing surgical mesh products for transvaginal repair of…
Headline
Updated preliminary results from studies to better understand how duodenoscopes are reprocessed in real-world settings continue to show higher than expected…